ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conferences

ImmunoGen, Inc. (Nasdaq: IMGN) announced today that Daniel Junius, President and CEO, will present at two investor conferences next week. These presentations will be webcast live and can be accessed through the “Investor Information” section of the Company’s website, www.immunogen.com. An archive of these webcasts will be available at the same location until June 18, 2010.

• Morgan Joseph Best Ideas ConferenceWednesday, June 9, 2010 at 3:00 p.m. ETNew York, NY
• Jefferies 2010 Global Life Sciences ConferenceThursday, June 10, 2010 at 4:30 p.m. ETNew York, NY

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s potent cell-killing agents specifically to tumor targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech/Roche. Other ImmunoGen collaborative partners include Bayer Schering Pharma and Amgen. More information about ImmunoGen can be found at www.immunogen.com.